Instem – interims, emphasises revenue increase and adjusted profit… but what about cash?
Earlier this month I concluded on company which describes itself as “a leading provider of IT solutions to the global life sciences market” Instem plc (INS) that, with the shares up to 660p, greater and more consistent delivery is required – in overall financial terms, not just contract announcements. Now half-year results...and the shares currently down to below 600p.
- By Steve Moore
- 2022-09-27 15:30:56